List of Excipients in Branded Drug VIMPAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
UCB Inc	VIMPAT	lacosamide	0131-2477	ALUMINUM OXIDE
UCB Inc	VIMPAT	lacosamide	0131-2477	CELLULOSE, MICROCRYSTALLINE
UCB Inc	VIMPAT	lacosamide	0131-2477	CROSPOVIDONE
UCB Inc	VIMPAT	lacosamide	0131-2477	FD&C BLUE NO. 2
UCB Inc	VIMPAT	lacosamide	0131-2477	FERRIC OXIDE RED
UCB Inc	VIMPAT	lacosamide	0131-2477	FERROSOFERRIC OXIDE

VIMPAT Excipient Strategy and Commercial Opportunities for Lacosamide

Last updated: August 9, 2026

VIMPAT is the branded formulation of lacosamide, an antiseizure medicine developed by UCB. Its commercial products include immediate-release tablets, an oral solution, and an intravenous injection. The core excipient opportunity is no longer protection of the original tablet formula. It is differentiation around pediatric administration, taste masking, preservative systems, ready-to-use parenteral delivery, manufacturing efficiency, and lifecycle formulations that can obtain separate regulatory or intellectual-property protection.

Generic lacosamide has materially reduced the value of the original VIMPAT formulation. Excipient suppliers and drug developers can still pursue opportunities because lacosamide is used across chronic outpatient therapy and acute hospital settings, where administration convenience, supply reliability, tolerability, and dosage flexibility influence product selection.

What is VIMPAT and which dosage forms use excipients?

VIMPAT contains lacosamide, a functionalized amino acid used for the treatment of partial-onset seizures. The U.S. product line consists of:

Dosage form	Strength or presentation	Primary commercial use	Excipient strategy
Film-coated tablets	50, 100, 150, and 200 mg	Chronic outpatient treatment	Compression, disintegration, coating, color coding
Oral solution	10 mg/mL	Pediatric, geriatric, and swallowing-impaired patients	Solubilization, sweetness, viscosity, preservation, flavor
Injection	200 mg/20 mL, 10 mg/mL	Hospital and acute-care use	Isotonicity, pH control, sterility, container compatibility

The U.S. prescribing information identifies conventional pharmaceutical excipients for these presentations. Tablet excipients include microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The film coating includes materials such as hypromellose or related coating polymers, polyethylene glycol, talc, titanium dioxide, and colorants. The oral solution uses water, glycerol, polyethylene glycol 400, sodium saccharin, methylparaben, and flavoring components. The injection contains sodium chloride and water for injection, with hydrochloric acid used for pH adjustment.[1]

The specific formulation is important for regulatory sameness, but excipients are not active ingredients and usually do not prevent an ANDA applicant from entering the market when the applicant can establish pharmaceutical equivalence and bioequivalence.

What excipients are used in VIMPAT tablets?

VIMPAT tablets use a conventional immediate-release platform. The formulation is designed to support high-volume manufacturing, rapid disintegration, dose uniformity, and color-based strength identification.

Tablet excipient functions

Excipient category	Representative VIMPAT material	Technical role
Diluent and compression aid	Microcrystalline cellulose	Tablet mass, compactability, mechanical strength
Binder	Hydroxypropyl cellulose	Granule and tablet cohesion
Disintegrant	Croscarmellose sodium and low-substituted hydroxypropyl cellulose	Water uptake and tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and die filling
Lubricant	Magnesium stearate	Ejection and tooling protection
Film coating	Hypromellose or related polymer, polyethylene glycol, talc	Surface protection, appearance, swallowability
Colorant	Approved inorganic or organic colorants	Strength differentiation and product identification

This formulation has limited differentiation value after generic entry. A generic manufacturer generally does not need to duplicate every inactive ingredient. Under the FDA’s ANDA framework, the product must meet applicable requirements for sameness, performance, labeling, and bioequivalence. Formulation changes can be acceptable when they do not alter the product’s quality or clinical performance.[2]

The commercial opportunity therefore lies in improving manufacturing or patient use rather than copying the branded tablet exactly.

What commercial opportunities exist for VIMPAT excipient suppliers?

The most credible opportunities are concentrated in oral liquids, pediatric dosage forms, orally disintegrating products, and hospital-ready injection systems.

Pediatric and swallowing-impaired formulations

Lacosamide is used in patients who may have difficulty swallowing conventional tablets. A liquid formulation can improve access for children, older adults, patients with neurological impairment, and patients receiving enteral nutrition.

Potential excipient opportunities include:

• Low-sugar or sugar-free vehicles
• Improved taste-masking systems
• Reduced-viscosity liquids compatible with oral syringes
• Preservative systems with lower sensory impact
• Suspensions or multiparticulate products for dose flexibility
• Metered-dose packaging
• Formulations compatible with feeding tubes

The existing VIMPAT oral solution uses a sweetening and flavor system with a preservative. A next-generation product could target lower excipient burden, improved palatability, or better stability after opening. These changes could support a 505(b)(2) strategy if the formulation provides a clinically or administratively meaningful difference, although the regulatory pathway would depend on the product’s claims and evidence package.[3]

Orally disintegrating tablets and mini-tablets

An orally disintegrating tablet, or ODT, could address patients with dysphagia without requiring a liquid bottle. Lacosamide’s relatively low dose range is compatible with ODT and mini-tablet design, subject to manufacturability and performance testing.

Relevant excipient technologies include:

• Co-processed mannitol-cellulose systems
• Crospovidone or optimized superdisintegrants
• Direct-compression platforms
• Taste-masking polymers
• Sublingual or buccal wetting systems
• Low-hygroscopicity fillers
• Robust packaging for moisture protection

An ODT would need to manage the drug’s taste, mechanical strength, friability, disintegration time, and dose uniformity. A weak ODT that breaks during packaging or has poor taste acceptance would have limited commercial value.

Sprinkle formulations

Multiparticulate lacosamide products could be designed for administration on soft food or through selected feeding tubes. The excipient and coating strategy would need to control:

• Drug release
• Taste exposure
• Particle segregation
• Dose recovery from the administration vehicle
• Tube adhesion
• Stability after opening
• Compatibility with common foods and enteral formulas

A sprinkle formulation may offer a clearer patient-use advantage than a conventional tablet while avoiding some of the packaging and stability issues associated with an oral liquid.

Hospital injection opportunities

The injection presentation creates a separate excipient and packaging market. Hospitals value ready-to-administer products that reduce preparation steps, medication errors, and pharmacy labor.

Potential products include:

• Premixed infusion bags
• Ready-to-use syringes
• Smaller-volume presentations
• Terminally sterilized presentations where feasible
• Low-waste containers
• Dual-chamber or closed-system transfer devices
• Packaging optimized for automated dispensing systems

For an injectable lacosamide product, the key technical constraints are pH, osmolality, particulate control, container closure integrity, extractables and leachables, sterilization compatibility, and stability under refrigerated or room-temperature conditions. Excipient changes must not increase precipitation, adsorption to the container, degradation, or infusion-line incompatibility.

What formulation patents protect VIMPAT and lacosamide products?

The original commercial value of VIMPAT was primarily tied to lacosamide composition-of-matter and use patents, rather than a highly differentiated excipient platform. UCB’s U.S. regulatory filings and the FDA Orange Book historically listed patents associated with VIMPAT. The relevant protection included drug substance and method-of-use claims, with patent litigation and settlement activity affecting the timing of generic entry.[4][5]

Excipient-specific patent protection is more difficult to enforce when the formulation uses standard materials such as microcrystalline cellulose, magnesium stearate, croscarmellose sodium, polyethylene glycol, and common coating polymers. Stronger formulation claims would generally require a defined combination or performance characteristic, such as:

• A specific taste-masking matrix
• A controlled-release profile
• A defined particle-size or coating architecture
• A stability-improving excipient combination
• A novel ready-to-administer parenteral presentation
• A feeding-tube-compatible multiparticulate formulation
• A preservative-free liquid with a specified shelf life
• A dosage form with defined disintegration and dissolution parameters

A formulation patent does not automatically prevent generic substitution. Its commercial value depends on claim scope, infringement exposure, Orange Book listing eligibility, litigation cost, and whether the product obtains meaningful prescription or formulary preference.

When did VIMPAT lose exclusivity and when did generic lacosamide enter?

VIMPAT received U.S. FDA approval in 2008. The product received five-year new chemical entity exclusivity, followed by pediatric exclusivity associated with FDA pediatric requirements. The original product also benefited from patent protection and regulatory litigation constraints.

Generic lacosamide products entered the U.S. market in 2022 after the principal exclusivity and patent barriers were exhausted or resolved. The market now includes generic tablets, oral solution, and injection products, subject to FDA approval and individual manufacturer launch decisions.[1][4]

Milestone	Approximate date	Commercial effect
FDA approval of VIMPAT	2008	U.S. launch of lacosamide
NCE exclusivity period	2008-2013	Delayed ANDA approval
Pediatric exclusivity period	2013	Extended applicable regulatory protection
Patent and Paragraph IV activity	Before generic entry	Defined settlement and launch timing
Generic lacosamide entry	2022	Reduced branded pricing power
Post-entry market	2022 onward	Shift toward cost, supply, dosage-form, and contracting advantages

Exact patent expiration dates can differ by patent, jurisdiction, patent-term adjustment, pediatric extension, and settlement terms. The FDA Orange Book remains the controlling source for listed U.S. patents and regulatory exclusivity status.[4]

Which companies are challenging VIMPAT through generic lacosamide?

Multiple generic manufacturers have entered or pursued lacosamide products in the United States. Generic competition has involved the principal dosage forms used by VIMPAT, including tablets, oral solution, and injection.

The commercial contest is not limited to the active ingredient. Manufacturers compete on:

• Wholesale acquisition cost
• Medicaid and commercial rebate structures
• Product availability
• National wholesaler coverage
• Hospital group purchasing contracts
• Oral-solution supply reliability
• Packaging and unit-dose formats
• Manufacturing-site redundancy
• Regulatory compliance history

Paragraph IV certifications are the main U.S. mechanism by which an ANDA applicant can challenge listed patents before expiration. A Paragraph IV filing can trigger Hatch-Waxman litigation and a potential 30-month stay of FDA approval, depending on the patent, timing, and statutory conditions.[5]

The branded VIMPAT estate is weaker against standard generic tablets than against differentiated lifecycle products. A new ODT, liquid, or hospital presentation would face a separate competitive analysis because the product could be protected by formulation, use, packaging, or device claims rather than only by the original lacosamide patents.

What is the Orange Book status of VIMPAT?

VIMPAT’s Orange Book status historically included listed patents and exclusivity information associated with lacosamide products. Orange Book listings matter because they identify patents that an ANDA applicant must address through a Paragraph IV certification or a certification that approval will be delayed until patent expiry.[4]

For excipient-focused opportunities, the key distinction is:

• A standard generic tablet generally relies on active-ingredient equivalence and does not need to duplicate the branded excipient profile.
• A proprietary formulation may qualify for separate patent claims if the formulation has a novel, non-obvious, and commercially relevant structure or performance.
• A 505(b)(2) product can rely partly on existing findings while pursuing a differentiated dosage form or route, but the sponsor must address applicable patents and provide supporting data.[3]

A formulation strategy should therefore begin with a patent claim chart covering the active ingredient, dosage form, manufacturing process, excipient combination, release profile, and administration method.

How strong is the VIMPAT patent estate for excipient-based competition?

The patent estate is stronger for the original lacosamide molecule and therapeutic use than for routine inactive ingredients. Standard excipients have extensive prior art and are difficult to protect broadly.

Patent strength for a new lacosamide formulation depends on five factors:

1. Whether the dosage form solves a documented administration problem.
2. Whether the excipient combination produces an unexpected technical result.
3. Whether the formulation can be claimed with objective parameters.
4. Whether the product can obtain meaningful clinical, payer, or hospital preference.
5. Whether the claims can be listed or enforced against competing products.

A formulation with only a different filler or lubricant is unlikely to create durable exclusivity. A formulation that improves pediatric adherence, feeding-tube delivery, taste, stability, or emergency administration has a stronger commercial and patent rationale.

What licensing opportunities exist for VIMPAT excipient technology?

Publicly documented licensing activity around VIMPAT’s original formulation is less commercially important than licensing for platform technologies. The most attractive partnering structures would involve:

• Taste-masking platforms licensed to a lacosamide product sponsor
• ODT manufacturing technology
• Multiparticulate coating systems
• Ready-to-use sterile filling and packaging
• Preservative-free liquid systems
• Excipient supply agreements with dual-source qualification
• Regional commercialization rights for pediatric or hospital formulations

An excipient supplier can pursue a supply-plus-license model when its value depends on both material quality and proprietary processing. Examples include co-processed excipients, coated drug particles, specialized polymers, and container-compatible sterile formulations.

The strongest licensing proposition would combine a defined technical benefit with a regulatory package, including analytical methods, stability data, scale-up parameters, and prior human-use experience.

How does lacosamide compare with other antiseizure drugs?

Lacosamide competes with levetiracetam, brivaracetam, lamotrigine, oxcarbazepine, and other antiseizure medicines. Many competing products are available as tablets, oral liquids, and injectable formulations.

Product category	Excipient opportunity	Competitive implication
Lacosamide tablets	ODT, mini-tablet, moisture protection	Convenience and adherence
Lacosamide oral solution	Taste masking, dosing accuracy, tube compatibility	Pediatric and geriatric use
Lacosamide injection	Premix, syringe, container compatibility	Hospital labor and safety
Levetiracetam	Broad generic availability and multiple liquids	Strong price competition
Brivaracetam	Branded differentiation and liquid/injection options	Higher-value specialty positioning
Lamotrigine	Complex titration and formulation considerations	Adherence and dosing flexibility

Lacosamide’s commercial position depends on generic price pressure, hospital purchasing, neurologist prescribing patterns, and the ability to offer a dosage form that solves a practical administration problem.

What generic launch risks exist for a new lacosamide product?

A new lacosamide product faces five major risks:

• A crowded generic market for conventional tablets
• Limited willingness to pay for minor excipient changes
• Failure to demonstrate bioequivalence or comparative performance
• Patent claims covering the proposed dosage form
• Manufacturing instability at commercial scale

The lowest-risk entry strategy is usually a conventional generic with a reliable supply chain. The higher-margin strategy is a differentiated formulation, but it requires stronger evidence and a clear customer segment.

For excipient companies, the most defensible opportunity is often upstream. Supplying a qualified, high-functionality excipient to multiple generic manufacturers can create recurring volume without taking full product liability and regulatory risk.

Key Takeaways

• VIMPAT is lacosamide in tablet, oral-solution, and injectable forms.
• Its original tablet excipient system is conventional and offers limited standalone patent value.
• Generic lacosamide entered the U.S. market in 2022, reducing the value of the original VIMPAT formulation.
• The strongest excipient opportunities are taste-masked liquids, ODTs, sprinkle products, feeding-tube-compatible formulations, and ready-to-use injections.
• Standard excipient substitutions rarely create durable exclusivity.
• Formulations with measurable improvements in adherence, administration, stability, or hospital workflow have stronger commercial and patent potential.
• The FDA Orange Book and Hatch-Waxman patent certifications remain central to U.S. launch planning.
• Excipient suppliers can capture value through platform licensing, supply agreements, and co-developed lifecycle products.

FAQs

Can a generic lacosamide manufacturer use different excipients from VIMPAT?

Yes. An ANDA applicant generally does not need to duplicate every inactive ingredient, provided the product meets FDA requirements for pharmaceutical equivalence, quality, performance, labeling, and bioequivalence.

Is there a commercial opportunity for a lacosamide preservative-free oral solution?

Yes. A preservative-free product could target patients with preservative sensitivity, repeated dosing, or long-term use. It would require an alternative microbial-control strategy, suitable packaging, and stability data.

Could an ODT version of lacosamide receive separate patent protection?

Yes, if the ODT includes a novel and non-obvious formulation or manufacturing architecture. Broad claims based only on the use of known disintegrants or mannitol would face substantial prior-art risk.

Do biosimilar rules apply to VIMPAT?

No. Lacosamide is a small-molecule drug, so generic-drug and Hatch-Waxman rules apply. Biosimilar pathways apply to biological products, not conventional lacosamide products.

Which lacosamide formulation has the highest excipient-driven value?

A hospital-ready injectable presentation or a pediatric taste-masked product has the clearest potential because each can reduce administration burden and address a defined customer need. Conventional tablet reformulation has lower differentiation value.

References

1. U.S. Food and Drug Administration. (2022). Vimpat (lacosamide) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2016). Guidance for industry: ANDAs for certain highly soluble, highly permeable drugs. FDA.

3. U.S. Food and Drug Administration. (2020). Applications covered by section 505(b)(2). FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2023). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Amendments. FDA.